Bristol's Brutal Patent Cliff
11:46–12:51 · 66s
Rachel details how expiring patents dragged Revlimid sales from $12 billion to $3 billion, illustrating Bristol-Myers’ current struggles.
11:46–12:51 · 66s
Rachel details how expiring patents dragged Revlimid sales from $12 billion to $3 billion, illustrating Bristol-Myers’ current struggles.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.